Zydus Lifesciences gets USFDA nod to market generic drugs

Zydus Lifesciences on Saturday said it has received approval from the US health regulator to market generic anti-parasitic and leprosy medications.

The company has received final approvals from the US Food and Drug Administration (USFDA) for Ivermectin Tablets (3 mg) and Dapsone Tablets (25 mg and 100 mg), the Ahmedabad-based drug said in a statement.

Ivermectin tablets are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans, specifically intestinal strongyloidiasis and onchocerciasis.